CALCULATE YOUR SIP RETURNS

Biocon Pharma Receives Key USFDA Approvals For Multiple Drugs

Written by: Team Angel OneUpdated on: Mar 5, 2025, 2:53 PM IST
Biocon Pharma has received final US FDA approval for Lenalidomide and Dasatinib, along with tentative approval for Rivaroxaban.
Biocon Pharma Receives Key USFDA Approvals For Multiple Drugs
ShareShare on 1Share on 2Share on 3Share on 4Share on 5

Biocon Pharma, a subsidiary of Biocon Limited, has received final approval from the US Food and Drug Administration (USFDA) for two important drug applications.

Drugs Details 

  • Lenalidomide Capsules in 2.5 mg,5 mg,10 mg,15 mg,20 mg and 25 mg: Used for treating various types of blood cancers and anemia related to myelodysplastic syndromes (MDS).  
  • Dasatinib Tablets in 20mg,50mg,70 mg, mg, 80 mg,100 mg,120 mg and 140 mg: A medication for Philadelphia chromosome-positive chronic myeloid leukemia (Ph+CML) and acute lymphoblastic leukemia (Ph+ALL).  

Tentative Approval for Rivaroxaban Tablets

Along with the final approvals, Biocon Pharma has also secured tentative approval for Rivaroxaban Tablets USP in different strengths. This drug is used to treat deep vein thrombosis, pulmonary embolism and to reduce stroke risk in certain heart conditions.  

Strengthening the Drug Portfolio

These approvals contribute to Biocon’s growing portfolio of complex and high-value drug products, reinforcing its expertise in the pharmaceutical sector.  

Share Performance 

As of March 05, 2025, at 11:55 AM, the shares of Biocon Ltd are trading at ₹319.45 per share, reflecting a surge of 1.48% from the previous day’s closing price. Over the past month, the stock has registered a loss of 18.14%. The stock’s 52-week high stands at ₹404.70 per share, while its low is ₹244.55 per share.

Conclusion 

These approvals enhance Biocon Pharma’s footprint in the US market, expanding its portfolio of complex drugs for critical diseases. This milestone reinforces its commitment to delivering high-quality, affordable healthcare solutions globally.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Published on: Mar 5, 2025, 2:53 PM IST

Team Angel One

Team Angel One is a group of experienced financial writers that deliver insightful articles on the stock market, IPO, economy, personal finance, commodities and related categories.

Know More

We're Live on WhatsApp! Join our channel for market insights & updates

Open Free Demat Account!

Join our 3 Cr+ happy customers

+91
Enjoy Zero Brokerage on Equity Delivery
4.4 Cr+DOWNLOADS
Enjoy ₹0 Account Opening Charges

Get the link to download the App

Get it on Google PlayDownload on the App Store
Open Free Demat Account!
Join our 3 Cr+ happy customers